162 related articles for article (PubMed ID: 2423869)
1. Effector mechanisms in myasthenia gravis: end-plate function after passive transfer of IgG, Fab, and F(ab')2 hybrid molecules.
Sterz R; Hohlfeld R; Rajki K; Kaul M; Heininger K; Peper K; Toyka KV
Muscle Nerve; 1986 May; 9(4):306-12. PubMed ID: 2423869
[TBL] [Abstract][Full Text] [Related]
2. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
Cole RN; Reddel SW; Gervásio OL; Phillips WD
Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
[TBL] [Abstract][Full Text] [Related]
3. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor.
Loutrari H; Kokla A; Tzartos SJ
Eur J Immunol; 1992 Sep; 22(9):2449-52. PubMed ID: 1516631
[TBL] [Abstract][Full Text] [Related]
4. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
[TBL] [Abstract][Full Text] [Related]
5. Passively transferred myasthenia gravis: protection of mouse endplates by Fab fragments from human myasthenic IgG.
Toyka KV; Löwenadler B; Heininger K; Besinger UA; Birnberger KL; Fateh-Moghadam A; Heilbronn E
J Neurol Neurosurg Psychiatry; 1980 Sep; 43(9):836-42. PubMed ID: 6252294
[TBL] [Abstract][Full Text] [Related]
6. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects.
Viegas S; Jacobson L; Waters P; Cossins J; Jacob S; Leite MI; Webster R; Vincent A
Exp Neurol; 2012 Apr; 234(2):506-12. PubMed ID: 22326541
[TBL] [Abstract][Full Text] [Related]
7. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation.
Drachman DB; Angus CW; Adams RN; Michelson JD; Hoffman GJ
N Engl J Med; 1978 May; 298(20):1116-22. PubMed ID: 643030
[TBL] [Abstract][Full Text] [Related]
8. Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments.
Glennie MJ; McBride HM; Worth AT; Stevenson GT
J Immunol; 1987 Oct; 139(7):2367-75. PubMed ID: 2958547
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies to calcium channels in type 1 diabetes mediate autonomic dysfunction by different mechanisms in colon and bladder and are neutralized by antiidiotypic antibodies.
Wan EC; Gordon TP; Jackson MW
J Autoimmun; 2008 Aug; 31(1):66-72. PubMed ID: 18472396
[TBL] [Abstract][Full Text] [Related]
10. Myasthenia gravis and myasthenic syndromes.
Engel AG
Ann Neurol; 1984 Nov; 16(5):519-34. PubMed ID: 6095730
[TBL] [Abstract][Full Text] [Related]
11. [The 2-phase action on mice of immunoglobulins isolated from the blood of a myasthenia patient].
Smirnov VA; Saĭkova LA; Lobzin VS
Biull Eksp Biol Med; 1988 Nov; 106(11):549-52. PubMed ID: 3196852
[TBL] [Abstract][Full Text] [Related]
12. [Antibodies in myasthenia gravis].
Eymard B
Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
[TBL] [Abstract][Full Text] [Related]
13. Passive transfer of seronegative myasthenia gravis to mice.
Burges J; Vincent A; Molenaar PC; Newsom-Davis J; Peers C; Wray D
Muscle Nerve; 1994 Dec; 17(12):1393-400. PubMed ID: 7969240
[TBL] [Abstract][Full Text] [Related]
14. [Identification of human platelet specific functional antibody and its fragments].
Chu XX; Hou M; Zhu YY; Peng J; Ji XB; Zhang F; Wang L
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3464-8. PubMed ID: 16686061
[TBL] [Abstract][Full Text] [Related]
15. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice.
Toyka KV; Drachman DB; Griffin DE; Pestronk A; Winkelstein JA; Fishbeck KH; Kao I
N Engl J Med; 1977 Jan; 296(3):125-31. PubMed ID: 831074
[TBL] [Abstract][Full Text] [Related]
16. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.
Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH
J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897
[TBL] [Abstract][Full Text] [Related]
17. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
Atassi MZ; Oshima M; Deitiker P
Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6.
Biesecker G; Gomez CM
J Immunol; 1989 Apr; 142(8):2654-9. PubMed ID: 2703710
[TBL] [Abstract][Full Text] [Related]
19. IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients.
Koneczny I; Stevens JA; De Rosa A; Huda S; Huijbers MG; Saxena A; Maestri M; Lazaridis K; Zisimopoulou P; Tzartos S; Verschuuren J; van der Maarel SM; van Damme P; De Baets MH; Molenaar PC; Vincent A; Ricciardi R; Martinez-Martinez P; Losen M
J Autoimmun; 2017 Feb; 77():104-115. PubMed ID: 27965060
[TBL] [Abstract][Full Text] [Related]
20. Experimental myasthenia: lack of correlation between the autoantibody titer and the reduction of acetylcholine-controlled ionic channels measured at functioning endplates.
Hohlfeld R; Sterz R; Kalies I; Wekerle H; Peper K
Muscle Nerve; 1983 Feb; 6(2):160-3. PubMed ID: 6304508
[No Abstract] [Full Text] [Related]
[Next] [New Search]
